Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD.

Jørgensen AP, Ueland T, Sode-Carlsen R, Schreiner T, Rabben KF, Farholt S, Høybye C, Christiansen JS, Bollerslev J.

J Clin Endocrinol Metab. 2013 Apr;98(4):E753-60. doi: 10.1210/jc.2012-3378. Epub 2013 Feb 22.

PMID:
23436915
2.

Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.

de Lind van Wijngaarden RF, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, van Leeuwen M, Haring DA, Bocca G, Mieke Houdijk EC, Hokken-Koelega AC.

J Clin Endocrinol Metab. 2009 Oct;94(10):3763-71. doi: 10.1210/jc.2009-0270. Epub 2009 Jul 21.

PMID:
19622627
3.

Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.

Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Van Alfen AA, Van Leeuwen M, Van Wieringen H, Wegdam-den Boer ME, Zwaveling-Soonawala N, Hokken-Koelega AC.

J Clin Endocrinol Metab. 2015 Apr;100(4):1609-18. doi: 10.1210/jc.2014-4347. Epub 2015 Feb 10.

PMID:
25668198
4.
5.
7.
9.

Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.

Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Frystyk J, Christiansen JS, Höybye C.

Growth Horm IGF Res. 2011 Aug;21(4):185-90. doi: 10.1016/j.ghir.2011.05.002. Epub 2011 Jun 12.

PMID:
21664161
10.
11.

Effect of genetic subtypes and growth hormone treatment on bone mineral density in Prader-Willi syndrome.

Khare M, Gold JA, Wencel M, Billimek J, Surampalli A, Duarte B, Pontello A, Galassetti P, Cassidy S, Kimonis VE.

J Pediatr Endocrinol Metab. 2014 May;27(5-6):511-8. doi: 10.1515/jpem-2013-0180.

PMID:
24515997
12.
13.

Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.

Mogul HR, Lee PD, Whitman BY, Zipf WB, Frey M, Myers S, Cahan M, Pinyerd B, Southren AL.

J Clin Endocrinol Metab. 2008 Apr;93(4):1238-45. doi: 10.1210/jc.2007-2212. Epub 2008 Jan 22.

PMID:
18211968
14.

Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.

Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Höybye C.

Endocrine. 2012 Apr;41(2):191-9. doi: 10.1007/s12020-011-9560-4. Epub 2011 Nov 12. Review.

PMID:
22081257
15.

Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment.

Boot AM, Nauta J, de Jong MC, Groothoff JW, Lilien MR, van Wijk JA, Kist-van Holthe JE, Hokken-Koelega AC, Pols HA, de Muinck Keizer-Schrama SM.

Clin Endocrinol (Oxf). 1998 Nov;49(5):665-72.

PMID:
10197084
16.

Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.

de Lind van Wijngaarden RF, Siemensma EP, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, Bocca G, Houdijk EC, Hoorweg-Nijman JJ, Vreuls RC, Jira PE, van Trotsenburg AS, Bakker B, Schroor EJ, Pilon JW, Wit JM, Drop SL, Hokken-Koelega AC.

J Clin Endocrinol Metab. 2009 Nov;94(11):4205-15. doi: 10.1210/jc.2009-0454. Epub 2009 Oct 16.

PMID:
19837938
18.

Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.

Höybye C, Hilding A, Jacobsson H, Thorén M.

Clin Endocrinol (Oxf). 2003 May;58(5):653-61.

PMID:
12699450
19.

The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study.

Drake WM, Rodríguez-Arnao J, Weaver JU, James IT, Coyte D, Spector TD, Besser GM, Monson JP.

Clin Endocrinol (Oxf). 2001 Apr;54(4):525-32.

PMID:
11318789
20.

Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.

Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E.

Eur J Endocrinol. 1999 Jun;140(6):545-54.

Items per page

Supplemental Content

Write to the Help Desk